The 2026 deadline for the European Union’s In Vitro Diagnostic Regulation (IVDR) is no longer a distant milestone. The shift from the IVDD (In Vitro Diagnostic Directive) to the IVDR represents an increase in scrutiny, evidence expectations and post-market accountability. Where once a small subset of legacy devices moved through the system with minimal oversight, today many high impact diagnostics must withstand a level of examination that interrogates every claim, assumption and data point.
If the regulatory landscape were a marathon, the finish line hasn’t moved - but the distance has tripled. Submission volumes have surged, technical requirements have deepened, and the required evidence has expanded significantly. What was previously a mostly self declared pathway has transformed into a legislative framework where notified body oversight is no longer the exception but the norm. The result? A system that demands earlier preparation, stronger evidence, and more rigorous lifecycle management.
The demands of Class C devices
Class C devices sit at the intersection of both innovation and clinical developments. They include infectious disease assays that guide isolation decisions, oncology markers that shape therapeutic pathways, and genetic tests that underpin personalized medicine. Their importance is matched only by their complexity.
Three primary drivers define the complexity of Class C devices:
- Breadth of scope - diverse clinical contexts, critical intended uses and severe consequences of error.
- Depth of evidence - analytical and clinical performance data must be comprehensive, defensible and meticulously documented, with a rigor that far exceeds lower-class categories.
- Regulatory rigor - the general safety and performance requirements (GSPRs) demand complete, coherent dossiers. Any gap, whether in performance evaluation data, post market performance follow up (PMPF) planning, or risk analysis, triggers a cascade of deficiency notices that can stall certification for months.
As these strands intertwine, review timelines inevitably lengthen. With the 2026 deadlines approaching, the pressure to submit a technically robust dossier intensifies.
The need for early, structured preparation
Notified body capacity under the IVDR remains constrained, with organizations continuing to expand their resources, designation scopes, and operational processes while simultaneously managing significant MDR workloads. The MDR transition showed what happens when limited capacity meets immature submissions: incomplete dossiers, long rounds of questions, and multi year delays in market access. Without early, disciplined preparation, the IVDR is on track to follow the same trajectory.
A credible certification plan needs to anchor itself to the legal deadline and work backward, building in time for internal quality checks, multiple review cycles, and the inevitable rounds of notified body queries and revisions. Manufacturers who act now will be better positioned to meet the upcoming deadlines, avoid capacity driven delays, and maintain their device on the EU market.
Certify with BSI: Early dialogue, more predictable outcomes
BSI holds a leadership position among EU designated notified bodies for IVDR Class C. Early engagement with BSI in 2026 yields three decisive benefits:
I. Predictability - experienced reviewers identify gaps early, compressing the overall review cycle.
II. Proactive Communication - through BSI Structured Dialogue, transparent, early discussion prevent the cascade of deficiency notices that derail late entrants.
III. Technical Depth - multidisciplinary expertise - including clinical experts, risk management and post market surveillance specialists - ensures your evidence package aligns with IVDR requirements.
This level of regulatory clarity strengthens confidence across stakeholders, from investors to hospital networks and procurement teams, by demonstrating control, readiness and continuity.
A roadmap for early engagement
- Begin with an internal audit: mapping every GSPR against your current documentation, identifying gaps in performance evaluation, PMPF planning, or risk analysis.
- Structure your dossier with clear, modular sections - device description, intended use, analytical and clinical performance, risk management, and post market strategy.
- Engage with a reputable notified body for a pre application meeting to outline your device, development status, and anticipate challenges.
- Request BSI Structured Dialogue to align expectations and understand the certification process and timeline.
- Throughout the review process, adopt a ‘no surprises’ mindset, using our notified body’s queries to refine alignment and maintain momentum.
With these steps embedded, the IVDR transition becomes a managed predictable pathway rather than a source of uncertainty.
Public scrutiny reinforces regulatory responsibility
Public scrutiny of medical device oversight has intensified, driven in part by high profile examinations of regulatory failure. The Bleeding Edge (2018), a documentary on safety failures in the US medical device industry, exposed systemic weaknesses: rushed approvals, limited clinical evidence, inadequate post market surveillance and poor transparency in safety reporting. These are exactly the structural gaps the IVDR seeks to close. Its core message resonates with today’s Class C IVD landscape: patient safety depends on robust, continuously reassessed, clinically anchored evidence.
The lesson is clear. Proactive evidence generation and early dialogue with an experienced notified body are now essential.
Emerging trends shaping Class C devices
The regulatory environment will continue to evolve. AI-driven diagnostics will require robust validation datasets and continuous learning controls. Digital health integration will expand post market surveillance obligations. Companion diagnostics will demand synchronized regulatory strategies across drug device combinations. Early engagement with a highly established, proactive notified body such as BSI, positions you to stay ahead of these evolutions.
Conclusion: Act early to shape your future
The 2026 IVDR deadline is closer than it appears when viewed through the lens of internal development cycles and the intrinsic complexity of Class C devices. Delaying engagement risks regulatory setbacks, loss of market share, and erosion of stakeholder confidence. This is the new reality for Class C: prepare earlier, demonstrate more, manage continuously.
BSI is ready to be your strategic expert. Our technical expertise, proactive communication, and proven track record provide the confidence needed to navigate the IVDR transition.
Take the first step today: contact BSI to schedule a meeting. Share a high level overview of your Class C device and documentation status, and begin a collaborative, transparent journey, that turns early engagement into regulatory compliance.
The future of in vitro diagnostics will be defined by those who act now. Choose BSI for your IVDR transition.
Reference
Dick, K. (Director). (2018). The Bleeding Edge [Documentary]. Netflix. https://www.netflix.com/title/80170862
About the author
Liz Harrison, BSI’s Global Head of IVD Devices, leads a global team of regulatory product experts, reviewers, and decision-makers across all types of in vitro diagnostic medical devices. With a background in molecular biology and deep expertise in infectious disease, human genetic testing, cancer, and companion diagnostics, she brings scientific depth and operational clarity to IVDR implementation. Liz’s leadership ensures that BSI’s conformity assessments reflect both regulatory expectations and clinical realities, supporting manufacturers in navigating complex evidence requirements with confidence and precision.
About BSI
At BSI, we set new standards for success by collaborating with a diverse range of clients and partners across multiple industries to help them enhance performance, meet regulatory expectations and achieve their goals. We guide organizations through the complexities of global requirements, supporting them to promote safety and strengthen resilience.
As the world’s first national standards body, our unrivalled global expertise and long standing commitment to public benefit and innovation continue to set the benchmark for regulatory excellence.
